International Journal of Radiation Oncology*Biology*Physics
Volume 34, Issue 4, 1 March 1996, Pages 867-872
Biology original contributionRadiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
References (27)
- et al.
Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells
Int. J. Radiat. Oncol. Biol. Phys.
(1990) - et al.
The effect of fluorodeoxyuridine on sublethal damage repair in human colon cancer cells
Int. J. Radiat. Oncol. Biol. Phys.
(1991) - et al.
Enchancement of X-ray induced DNA damage by pretreatment with halogenated pyrimidine analogs
Int. J. Radiat. Oncol. Biol. Phys.
(1987) - et al.
Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine)
Cancer Treat. Rev.
(1993) - et al.
The role of cell cycle redistribution in radiosensitization: Implications regarding the mechanism of fluorodeoxyuridine radiosensitization
Int. J. Radiat. Oncol. Biol. Phys.
(1994) - et al.
Correlation of exposure time, concentration, and incorporation of IdUrd in V-79 cells with radiation response
Int. J. Radiat. Oncol. Biol. Phys.
(1989) - et al.
Decrease in TTP pools mediated by 5-bromo-2′-deoxyuridine exposure in a human glioblastoma cell line
Biochem. Pharmacol.
(1992) - et al.
Variations in several responses of HeLa cells to X-irradiation during the division cycle
Biophys. J.
(1963) - et al.
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
J. Clin. Oncol.
(1991) - et al.
2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase
J. Med. Chem.
(1991)
Mean inactivation dose: A useful concept for intercomparison of human cell survival curves
Radiat. Res.
(1984)
Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides
Cancer Res.
(1990)
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine
Mol. Pharmacol.
(1990)
Cited by (298)
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
2020, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :In this phase 1/2 trial, a 5-week course of intensity modulated radiation therapy (IMRT) (50-57.5 Gy) was given concurrently with weekly fixed-dose-rate (FDR) gemcitabine (1,000 mg/m2 over 100 minutes). FDR gemcitabine infusion likely increases intratumoral concentration of its active metabolite and enhances effects of radiation.16,17 This treatment resulted in a subsequent resection in 12 of 50 patients (24%), with resultant median OS of 32 months in that small cohort.18
Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer
2019, Radiotherapy and OncologyThe Evolving Role of Radiation in Pancreatic Cancer
2018, Surgical Clinics of North AmericaOverview
2015, Clinical Radiation Oncology
Copyright © 1996 Published by Elsevier Inc.